

Paul E Greenberg

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11812637/paul-e-greenberg-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

34
papers

5,276
citations

20
h-index

38
g-index

38
ext. papers

5,969
ext. citations

3.4
avg, IF

5.31
L-index

| # | Paper | IF | Citations |
|----|---|-----|-----------|
| 34 | Economic Burden of Commercially Insured Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior in the United States.. <i>Journal of Clinical Psychiatry</i> , 2022 , 83, | 4.6 | 2 |
| 33 | The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018). <i>Pharmacoeconomics</i> , 2021 , 39, 653-665 | 4.4 | 38 |
| 32 | Healthcare resource utilization and costs associated with postpartum depression among commercially insured households. <i>Current Medical Research and Opinion</i> , 2020 , 36, 1707-1716 | 2.5 | 4 |
| 31 | Medicaid spending burden among beneficiaries with treatment-resistant depression. <i>Journal of Comparative Effectiveness Research</i> , 2019 , 8, 381-392 | 2.1 | 16 |
| 30 | Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis. <i>PLoS ONE</i> , 2019 , 14, e0223255 | 3.7 | 18 |
| 29 | Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database. <i>Journal of Clinical Psychiatry</i> , 2018 , 79, | 4.6 | 67 |
| 28 | The economic burden of adults with major depressive disorder in the United States (2005 and 2010). <i>Journal of Clinical Psychiatry</i> , 2015 , 76, 155-62 | 4.6 | 988 |
| 27 | Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram. <i>American Health and Drug Benefits</i> , 2011 , 4, 78-87 | 1.7 | 1 |
| 26 | Assessing the relationship between compliance with antidepressant therapy and employer costs among employees in the United States. <i>Journal of Occupational and Environmental Medicine</i> , 2010 , 52, 115-24 | 2 | 12 |
| 25 | Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance. <i>Depression and Anxiety</i> , 2010 , 27, 78-89 | 8.4 | 257 |
| 24 | The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 2317-28 | 4 | 18 |
| 23 | Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs. <i>Journal of Medical Economics</i> , 2009 , 12, 124-35 | 2.4 | 17 |
| 22 | Determinants of direct cost differences among US employees with major depressive disorders using antidepressants. <i>Pharmacoeconomics</i> , 2009 , 27, 507-17 | 4.4 | 22 |
| 21 | Antidepressant treatment patterns and costs among US employees. <i>Journal of Medical Economics</i> , 2009 , 12, 36-45 | 2.4 | 2 |
| 20 | Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population. <i>Current Medical Research and Opinion</i> , 2008 , 24, 2587-95 | 2.5 | 20 |
| 19 | Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. <i>Archives of General Psychiatry</i> , 2007 , 64, 543-52 | | 1666 |
| 18 | Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective. <i>Clinical Journal of Pain</i> , 2006 , 22, 667-76 | 3.5 | 114 |

| | | | |
|----|--|------|-----|
| 17 | The Economic Burden of Depression: Societal and Patient Perspectives 2005 , 33-45 | | |
| 16 | The economic burden of depression in the US: societal and patient perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 369-76 | 4 | 108 |
| 15 | Economic consequences of not recognizing bipolar disorder patients: a cross-sectional descriptive analysis. <i>Journal of Clinical Psychiatry</i> , 2003 , 64, 1201-9 | 4.6 | 64 |
| 14 | The economic burden of depression in the United States: how did it change between 1990 and 2000?. <i>Journal of Clinical Psychiatry</i> , 2003 , 64, 1465-75 | 4.6 | 925 |
| 13 | Economic burden of respiratory infections in an employed population. <i>Chest</i> , 2002 , 122, 603-11 | 5.3 | 46 |
| 12 | Direct and indirect costs of asthma to an employer. <i>Journal of Allergy and Clinical Immunology</i> , 2002 , 109, 264-70 | 11.5 | 62 |
| 11 | Identification of a claims data "signature" and economic consequences for treatment-resistant depression. <i>Journal of Clinical Psychiatry</i> , 2002 , 63, 717-26 | 4.6 | 62 |
| 10 | Economic burden of pneumonia in an employed population. <i>Archives of Internal Medicine</i> , 2001 , 161, 2725-31 | | 30 |
| 9 | Assessing the economic impact of psychiatric disorders: where to begin?. <i>Expert Opinion on Pharmacotherapy</i> , 2001 , 2, 641-52 | 4 | |
| 8 | Cost of depression: current assessment and future directions. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2001 , 1, 69-76 | 2.2 | 10 |
| 7 | Depression and work productivity: the comparative costs of treatment versus nontreatment. <i>Journal of Occupational and Environmental Medicine</i> , 2001 , 43, 2-9 | 2 | 135 |
| 6 | Impact of illness and its treatment on workplace costs: regulatory and measurement issues. <i>Journal of Occupational and Environmental Medicine</i> , 2001 , 43, 56-63 | 2 | 20 |
| 5 | Management of Major Depression in the Workplace. <i>Disease Management and Health Outcomes</i> , 2000 , 7, 163-171 | | 16 |
| 4 | Direct and indirect costs of rheumatoid arthritis to an employer. <i>Journal of Occupational and Environmental Medicine</i> , 2000 , 42, 588-96 | 2 | 48 |
| 3 | Depression in the workplace: effects on short-term disability. <i>Health Affairs</i> , 1999 , 18, 163-71 | 0 | 262 |
| 2 | Using healthcare claims data for outcomes research and pharmacoeconomic analyses. <i>Pharmacoeconomics</i> , 1999 , 16, 1-8 | 4.4 | 78 |
| 1 | Workplace performance effects from chronic depression and its treatment. <i>Journal of Health Economics</i> , 1998 , 17, 511-35 | 3.5 | 143 |